Summit Therapeutics' stock price tumbled nearly 20% after the closing bell Thursday afternoon, catching investors off guard. The sharp decline followed an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.
The miss signals potential investor frustration over the drug's efficacy data, according to Endpoints News. Ivonescimab, a key pipeline asset for the biotech firm, has been under close scrutiny as a potential treatment for certain cancers.
Specific details on the exact endpoint or patient subgroup that failed remain limited in the source coverage. The company has not yet released a full dataset or formal statement explaining the interim results.
The stock drop suggests growing market skepticism about ivonescimab's prospects, though the drug has shown promise in other settings. Investors will likely await more complete trial data before reassessing the risk profile.
Further clarity may emerge if Summit Therapeutics provides additional analysis or plans for the trial in upcoming days. Analysts caution the miss may not jeopardize the entire development program.